

# Ashley M Schnakenberg-Martin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7333973/publications.pdf>

Version: 2024-02-01

24  
papers

698  
citations

759233

12  
h-index

677142

22  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1106  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metacognition, Adaptation, and Mental Health. <i>Biological Psychiatry</i> , 2022, 91, e31-e32.	1.3	6
2	Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior. <i>Cannabis and Cannabinoid Research</i> , 2022, , .	2.9	0
3	The relationship between cannabis use and taurine: A MRS and metabolomics study. <i>PLoS ONE</i> , 2022, 17, e0269280.	2.5	1
4	Altered cerebellar-cortical resting-state functional connectivity in cannabis users. <i>Journal of Psychopharmacology</i> , 2021, 35, 823-832.	4.0	9
5	Differential Cognitive Performance in Females and Males with Regular Cannabis Use. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 570-580.	1.8	6
6	Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and Posttraumatic stress disorder: A review. <i>Addictive Behaviors</i> , 2021, 122, 107026.	3.0	6
7	Individuals with psychosis and a lifetime history of cannabis use show greater deficits in emotional experience compared to non-using peers. <i>Journal of Mental Health</i> , 2020, 29, 77-83.	1.9	3
8	An investigation of the relationship between glutamate and resting state connectivity in chronic cannabis users. <i>Brain Imaging and Behavior</i> , 2020, 14, 2062-2071.	2.1	12
9	In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. <i>Psychopharmacology</i> , 2020, 237, 3097-3107.	3.1	7
10	Meaning, integration, and the self in serious mental illness: Implications of research in metacognition for psychiatric rehabilitation.. <i>Psychiatric Rehabilitation Journal</i> , 2020, 43, 275-283.	1.1	27
11	Metacognition and recovery in schizophrenia: From research to the development of metacognitive reflection and insight therapy. <i>Journal of Experimental Psychopathology</i> , 2019, 10, 204380871881499.	0.8	34
12	Aberrant structuralâ€“functional coupling in adult cannabis users. <i>Human Brain Mapping</i> , 2019, 40, 252-261.	3.6	24
13	The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. <i>Psychopharmacology</i> , 2018, 235, 1923-1932.	3.1	162
14	Auditory feature perception and auditory hallucinatory experiences in schizophrenia spectrum disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 653-661.	3.2	11
15	The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. <i>Psychiatry Research</i> , 2017, 250, 92-98.	3.3	10
16	Acute Phencyclidine Alters Neural Oscillations Evoked by Tones in the Auditory Cortex of Rats. <i>Neuropsychobiology</i> , 2017, 75, 53-62.	1.9	1
17	Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 176-183.	4.8	27
18	Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. <i>Schizophrenia Research: Cognition</i> , 2016, 6, 15-21.	1.3	16

#	ARTICLE	IF	CITATIONS
19	GABA Deficits Enhance the Psychotomimetic Effects of $\Delta^9$ -THC. <i>Neuropsychopharmacology</i> , 2015, 40, 2047-2056.	5.4	29
20	Effects of $\Delta^9$ -tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism. <i>Psychopharmacology</i> , 2014, 231, 2385-2393.	3.1	7
21	Acute effects of THC on time perception in frequent and infrequent cannabis users. <i>Psychopharmacology</i> , 2013, 226, 401-413.	3.1	76
22	Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous $\Delta^9$ -THC in Humans. <i>Neuropsychopharmacology</i> , 2012, 37, 1632-1646.	5.4	89
23	Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the $\mu$ Opioid Agonist Salvinorin A in Humans. <i>Biological Psychiatry</i> , 2012, 72, 871-879.	1.3	106
24	The safety of studies with intravenous $\Delta^9$ -tetrahydrocannabinol in humans, with case histories. <i>Psychopharmacology</i> , 2012, 219, 885-896.	3.1	29